Study BT7480-100 in Patients With Advanced Malignancies Associated With Nectin-4 Expression
Sponsor: BicycleTx Limited
ClinicalTrials ID:NCT05163041
This Phase 1/2 study evaluates BT7480, alone and with nivolumab, in patients with advanced Nectin-4 expressing tumors. It assesses safety, dosage, and effects, including in those with renal insufficiency. Eligible participants have refractory metastatic disease, ECOG 0-1, and must provide tumor tissue. BT7480 is given weekly; nivolumab biweekly.
Patient Parameters
| Parameter | Options |
|---|
Program Overview
This clinical study is evaluating a drug called BT7480 alone and in combination with nivolumab in participants with advanced solid tumors associated with Nectin-4 expression.
The main goals of the study are to:
- Find the recommended dose of BT7480 that can be given safely to participants alone and in combination with nivolumab
- Learn about the side effects and effectiveness of BT7480 alone and in combination with nivolumab
- Learn about the effect BT7480 has on the body and how BT7480 is cleared by the body
- Learn about the side effects and effectiveness of BT7480 in patients with reduced kidney function
Description
BT7480 is a tumor targeted immune cell agonist consisting of three bicyclic peptides (Bicycle®) conjugated via a linker, one that binds selectively to Nectin-4 and two that bind to CD137.
This study is a Phase 1/2, multicenter, first-in-human, open-label study of BT7480 given as a single agent and in combination with nivolumab once weekly. There are five parts to the trial: 1) Phase 1 dose escalation in patients with select advanced solid tumors primarily to evaluate safety and tolerability of BT7480 as a monotherapy and determine a recommended Phase 2 dose (RP2D); 2) Phase 1 dose escalation in combination with nivolumab, once the monotherapy RP2D has been determined; 3) Phase 2 dose expansion as a monotherapy once the RP2D has been determined; 4) Phase 2 dose expansion in combination with nivolumab; 5) Phase 1 monotherapy dose confirmation in patients with renal insufficiency once the monotherapy RP2D has been determined
Eligibility Criteria
Inclusion Criteria
- Must have locally advanced or metastatic disease that is refractory to standard therapy, or for which no standard therapy is judged to be appropriate or provide clinical benefit, as judged by the Investigator
- Must have a histologically or cytologically confirmed malignant solid tumor associated with Nectin-4 expression, including, but not limited to, urothelial (transitional cell) carcinoma; head and neck squamous cell carcinoma; non-small cell lung cancer; and ovarian, breast, gastric, or esophageal carcinoma
- Must have ECOG performance status score 0 or 1 and acceptable organ and hematological function
- Must have metastatic or locally advanced disease and measurable disease per Response Evaluation Criteria in Solid Tumors (RECIST) 1.1
- Life expectancy ≥12 weeks
- Must submit fresh or archival tumor tissue
- Must provide written informed consent, according to local guidelines, signed and dated by the patient or by a legal guardian prior to the performance of any study-specific procedures, sampling, or analysis
Exclusion Criteria
- Prior therapy with a cytotoxic, small molecule, or other systemic chemotherapy within 14 days of the first dose of study drug
- Prior immunotherapy, including monoclonal antibodies, within 28 days or 5 half-lives of the first dose of study drug, whichever is shorter
- Prior treatment with CD137 targeted therapy
- Mean resting QTc (eg, QTcF) greater than 470 msec on triplicate electrocardiograms (ECGs) obtained at screening
- Uncontrolled symptomatic brain metastases
- Uncontrolled diabetes with glycosylated hemoglobin greater than or equal to 8%
- Uncontrolled hypertension at screening or prior to initiation of study drug
- History of autoimmune disease except well-controlled diabetes mellitus, alopecia, well controlled thyroid disease or vitiligo
Get This Program In Your Inbox
You can sign up and apply your patients for this program.